We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD). (PHI-IMD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00979706
First Posted: September 18, 2009
Last Update Posted: November 19, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Juan A. Arnaiz, Hospital Clinic of Barcelona
September 16, 2009
September 18, 2009
November 19, 2014
March 2005
November 2014   (Final data collection date for primary outcome measure)
Proportion of patients remaining below 5,000 copies/mL at 12 and 48 weeks after stoping HAART. [ Time Frame: W12 y W48 ]
Same as current
Complete list of historical versions of study NCT00979706 on ClinicalTrials.gov Archive Site
  • Adherence to treatment [ Time Frame: W8, W24, W36, W96 ]
  • CD4, CD8 [ Time Frame: W8, W24, W36, W96 ]
  • Specific HIV immune responses (CD4 and CTL) [ Time Frame: W8, W24, W36, W96 ]
  • Proportion of patients PVL (plasma viral load)<40 [ Time Frame: W8, W24, W36, W96 ]
  • Adverse events [ Time Frame: W8, W24, W36, W96 ]
Same as current
Not Provided
Not Provided
 
Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).
Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection With the Objective to Induce a Strong Specific HIV Immune Response Able to Control Viral Replication Without Highly Active Anti-Retroviral Therapy (HAART)
Pilot study for the treatment of primary HIV infection with the objective to induce a strong specific HIV immune response able to control viral replication without HAART.
Pilot and open RCT in 20 patients with primary HIV-1 infection who were randomized to one of these two arms: 1) Control arm (A), Tenofovir +Lamivudine + Lopinavir-ritonavir (Kaletra) at standard doses for 44 weeks (W44); a short treatment interruption (TI) was performed at W36, and HAART was restarted for 8 weeks when plasma HIV-1 RNA viral load (pVL) rebounded>200 copies/mL. At W44 HAART was stopped and patients were followed for 48 additional weeks (W92). 2) Immune-based arm (B), same HAART schedule plus oral cyclosporine A (CsA)(serum levels 250-350 mcg/L) for the first 8 weeks of HAART. During the TI, patients received sc GM-CSF (250 mcg TIW) plus weekly sc pegylated-interferon a2b (Peg-INF)(1.5 mcg/kg/week). During the last 8 weeks of HAART (until W44), patients received daily sc low-dose interleukin-2 (IL-2)(0.75 MU/kg QD). The primary endpoint was pVL <1000copies/mL (<3.0 log10/mL) at 12 (W56) and at 48 (W92) weeks after stopping HAART. Sample size was calculated in order to detect a pVL difference of 1.5log10 copies/mL at 12 (W56) weeks after stopping HAART between the control and the immune-based arms with a power of 80% and a level of significance of0.05.
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
HIV
  • Drug: HAART

    Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.

    All patients will be followed-up during 1 year.

    Other Names:
    • Viread
    • Epivir
    • Kaletra
  • Drug: HAART + Immunotherapy

    Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.

    All patients will be followed-up during 1 year.

    Other Names:
    • Cyclosporine A
    • GM-CSF
    • Peg-IFN
    • Interleukin-2
  • Active Comparator: HAART
    Patients assigned to this arm will receive standard HAART
    Intervention: Drug: HAART
  • Experimental: HAART + Immunotherapy
    Patients assigned to this arm will receive HAART plus cyclosporin A during the first two months and after that will receive IFN, GM-CSF and IL-2.
    Intervention: Drug: HAART + Immunotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
22
November 2014
November 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. HIV-infected patients (age 18 years or over) with primary HIV infection <90 days.
  2. Giving written informed consent to participate into the study.

Exclusion Criteria:

  1. Patients not accepting to start HAART. Patients wishing start HAART treatment with nevirapine or efavirenz.
  2. Pregnant women or planning pregnancy.
  3. Intravenous drug user or alcohol abuse.
  4. Previous treatment with cyclosporin A, GM-CSF,pegylated-interferon-alpha o interleukine-2.
  5. Renal or liver failure.
  6. Any formal contraindication to treatment with the study drugs.
  7. Patients with a history of psychiatric disorder, thyroid illness, dislipidemia requiring treatment, cardiovascular disease, arterial hypertension, or diabetes mellitus.
  8. In treatment with drugs interacting with study drugs.
  9. Acute infection for HTLV-I or EBV.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT00979706
PHI-INMUNOMEDIADO
Yes
Not Provided
Not Provided
Juan A. Arnaiz, Hospital Clinic of Barcelona
Juan A. Arnaiz
Not Provided
Principal Investigator: Josep Maria Miró, MDPhD Hospital Clinic of Barcelona
Hospital Clinic of Barcelona
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP